A 49-year-old female client presents to the PMHNP for a medication evaluation prior to beginning treatment for rheumatoid arthritis. As they are reviewing her psychiatric medications, the client says, "I also take melatonin, but that probably doesn't matter." What is the most appropriate response from the PMHNP?

Choice A reason: While melatonin is generally considered safe for short-term use, it has clinically significant interactions with several medications, including immunosuppressants. It can stimulate immune function, which may counteract the effects of immunosuppressive therapy. Therefore, this response is overly dismissive and potentially unsafe. Choice B reason: Melatonin can interfere with immunosuppressive therapy by enhancing immune activity, which is counterproductive in conditions like rheumatoid arthritis where immunosuppression is often necessary. This makes it contraindicated or at least a cautionary supplement in such contexts. The PMHNP should recognize this and advise accordingly. Choice C reason: While deferring to the primary care provider may seem prudent, the PMHNP is qualified to assess drug interactions and should take responsibility for evaluating the safety of melatonin in this context. This response lacks clinical assertiveness. Choice D reason: Suggesting a benzodiazepine as a replacement for melatonin without assessing the client’s full psychiatric and medical profile is inappropriate. Benzodiazepines carry risks of dependence and sedation and are not a direct substitute for melatonin in most cases.